Loargys
What Loargys is used for
Loargys is indicated for the treatment of arginase 1 deficiency (ARG1 D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Loargys
- Active substance
- pegzilarginase
- Disease area
- Hyperargininemia
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB24
- Marketing authorisation holder
- Immedica Pharma AB
- Authorised in the EU since
- 2023
Official information
In the USA
Same active substance: Loargys
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Loargys used for?
Loargys is indicated for the treatment of arginase 1 deficiency (ARG1 D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older.
What is the active substance in Loargys?
Loargys contains pegzilarginase.
Who makes Loargys?
The EU marketing authorisation holder is Immedica Pharma AB.
Is Loargys an orphan medicine?
Yes. Loargys is designated an orphan medicine in the EU, for a rare disease (Hyperargininemia).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU